Ética de la prescripción. Conflictos del médico con el paciente, la entidad gestora y la industria farmacéutica

Medicina Clinica

Volumn 116, Issue 8, 2001, Pages 299-306

  Martín Moreno, Santiago ^a  

^a HOSPITAL GENERAL DE SEGOVIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO;

ADVERTIZING; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; DOCTOR PATIENT RELATION; DRUG COST; DRUG INDUSTRY; ECONOMICS; HUMAN; MASS MEDIUM; MEDICAL ETHICS; PRESCRIPTION; SPAIN; UNITED STATES;

ADVERTISING; CLINICAL TRIALS; DRUG COSTS; DRUG INDUSTRY; ETHICS, MEDICAL; HUMANS; MASS MEDIA; PHYSICIAN-PATIENT RELATIONS; PLACEBOS; PRESCRIPTIONS, DRUG; SPAIN; UNITED STATES;

EID: 0035799243     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0025-7753(01)71806-4     Document Type: Article

References (65)

1. Gracia D. Ética y responsabilidad profesional (Cap. 2). En: Profesión médica, investigación y justicia sanitaria. Bogotá: El Buho, 1998.
2. Rothman DJ. Medical professionalism. Focusing on the real issues. N Engl J Med 2000; 342: 1284-1286.
3. Wynia MK, Latham SR, Kao AC, Berg JW, Emanuel LL. Medical professionalism in society. N Engl J Med 1999; 341: 1612-1615.
4. Gracia D. Primum non nocere. El principio de no maleficencia como fundamento de la ética médica. Discurso para la recepción pública en la Real Academia Nacional de Medicina. Madrid, 1990.
5. Barber N. What constitutes good prescribing? Br Med J 1995; 310: 923-925.
6. Bodenheimer T. Uneasy alliance. Clinical investigators and the pharmaceutical industry. N Engl J Med 2000; 342: 1539-1544.
7. Bobbio M, Demichelis B, Giustetto G. Completeness of reporting trial results: effect on physicians' willingness to prescribe. Lancet 1994; 343: 1209-1211.
8. Gottlieb S. Medical societies accused of being beholden to the drugs industry. Br Med J 1999; 319: 1321.
9. Angell M. Is academic medicine for sale? N Engl J Med 2000; 342: 1516-1518.
10. Stelfox HT, Chua G, O'Rourke K, Detsky AS. Conflict of interest in the debate over calcium-chanel antagonists. N Engl J Med 1998; 338: 101-106.
11. Friedberg M, Saffran B, Stinsons TJ, Nelson W, Bennett CL. Evaluation of conflict of interest of economic analyses of new drugs used in oncology. JAMA 1999; 282: 1453-1457.
12. Schneiderman LJ, Jecker NS, Jonsen AR. Medical futility: its meaning and ethical implications. Ann Intern Med 1990; 112: 949-954.
13. Billings JA, Stoeckle JD. The clinical encounter. A guide to the medical interview and case presentation. Chicago: Year Book Medical Publishers. Inc, 1989; 203-204.
14. Emanuel EJ, Emanuel LL. Four models of the physician-patient relationship. JAMA 1992; 267: 2221-2226.
15. Lowenthal JF, Caranasos GJ. Pharmaceutics. II Issues in prescribing. En: Encyclopedia of bioethics. Nueva York: Macmillan Library Reference, 1995.
16. Howard Brody. Placebo. En: Encyclopedia of bioethics. Nueva York: Macmillan Library Reference, 1995.
17. Goodwin JS, Goodwin JM, Vogel AV. Knowledge and use of placebos by house officers and nurses. Ann Intern Med 1979; 91: 106-110.
18. Soriguer Escofet F. Uso y abuso del placebo. Med Clin (Barc) 1995: 104: 576-577.
19. Shortell SM, Waters TM, Clarke KW, Budetti PP Physicians as double agents. Maintaning trust in an era of multiple accountabilities. JAMA 1998; 280: 1102-1108.
20. Hampton JR. The end of clinical freedom Br Med J 1983; 287: 1237-1238.
21. Williams A. Health economics: the end of clinical freedom? Br Med J 1988; 297: 1183-1186.
22. Doctor Discontent. N Engl J Med 1999; 340: 649-653.
23. Gumbach K, Osmond D, Vranizan K, Jaffe D, Bindman AB. Primary care physicians' experience of financial incentives in managed-care systems. N Engl J Med 1998; 339: 1543-1545.
24. Garber AM. Using cost-effectiveness analysis to target cholesterol reduction. Ann Intern Med 2000; 132: 833-835.
25. Prasser LA, Stinnett AA, Goldman PA, Williams LW, Hunink MGM, Goldman L et al. Cost effectiveness of cholesterol-lowering therapies according to selected patients characteristics. Ann Intern Med 2000; 132: 769-779.
26. Gracia D. Ética de la eficiencia (Cap. 9). En : Profesión médica, investigaciôn y justicia sanitaria. Bogotá: El Buho, 1998.
27. Maestro A. Los profesionales, pieza clave para la privatización de la sanidad. El Médico. Anuario 2000: 28-32.
28. DeAngelis CD. The plight of academic health centers. JAMA 2000; 283: 2438-2439.
29. Feldman DS, Novack DH, Gracely E. Effects of managed care on physician-patient relationships, quality of care, and the ethical practice of medicine. Arch Intern Med 1998; 158: 1626-1632.
30. Editorial. Relación con la industria farmacéutica: ¿un dilema ético? Aten Primaria 2000; 25: 135-136.
31. Angell M. The pharmaceutical industry - To whom is it accountable? N Engl J Med 2000; 342: 1902-1904.
32. Gerth J. Stolberg SG. Drug companies profit from researsch supported by taxpayers. The New York Times, 23 de abril de 2000.
33. Editorial. Hacia un nuevo modelo de relación: médicos de familia/industria farmacéutica. Aten Primaria 1997; 19: 334-336.
34. Lexchin J. How patient outcomes are reported in drug advertisements: review of Canadian Medical Journals. Can Fam Phys 1999; 45: 1213-1216.
35. Bobbio M. Demicheli B, Giustetto G. Completeness of reporting trial results: effects on physicians' willingness to prescribe. Lancet 1994; 343: 1209-1211.
36. Griffith D. Reasons for not seeing drug representatives. Br Med J 1999; 319: 69-70.
37. Tiner R. Reasons for not seeing drug representatives. Br Med J 1999; 319: 1002.
38. Moynihan R, Bero L, Ross-Degnan D, Henry D, Kuiby Lee ChB, Watkins JBA et al. Coverage by the news media of the benefits and risks of medications. N Engl J Med 2000; 342: 1645-1650.
39. Tanne JH. Direct to consumer drug advertising is billion dollar business in US. Br Med J 1999; 319: 805.
40. User's Guide to the Medical Literature MCXXVIII: how to read pharmaceutical advertisements. http://www.nofreelunch.org/userguide.htm
41. Bell RA, Kravitz RL, Wilkes MS. Direct-to-consumer prescription drug advertising and the public. J Gen Intern Med 1999; 14: 651-657.
42. Spurgeon D. Doctors feel pressurised by direct to consumer advertising. Br Med J 1999; 319: 1321.
43. Siegel-Itzkovich. Doctors banned from drug company trip. Br Med J 1998; 317: 370.
44. Tenery RM. Interactions between physicians and the health care technology industry. JAMA 2000; 283: 391-393.
45. American College of Physicians. Position Paper. Physicians and the Pharmaceutical Industry. Ann Intern Med, 1990; 112: 624-626.
46. Sector Farmacéutico: evolución del consumo farmacéutico en gasto. En: Anuario de la Sanidad y del Medicamento en España. Madrid: SANED, 2000. El Médico 2000; 756 (Supl): 186.
47. Kotakk CP. Sistemas económicos: distribución, intercambio. En: Antropología. Una exploración de la diversidad humana. México: Mc Graw Hill, 1994.
48. Bohanann P, Glazer M. Marcel Mauss 1872-1950. En: Antropología. Lecturas. México: Mc Graw Hill, 1994.
49. María Moliner. Diccionario de uso del español. Madrid: Gredos, 1984.
50. Waud. DR. Pharmaceutical promotions. A free lunch? N Engl J Med 1992; 327: 351-354.
51. Chren M, Landefeld C, Murray T. Doctors, drug companies and gifts. JAMA 1989; 262: 3448-3451.
52. Randall T. Kennedy hearings say no more free lunh - or much else -from drug firms. JAMA 1991; 265: 440-441.
53. Dacso CC, Rodning CB. A physician/medical industrial ethos. Am J Med 1985; 79: 675.
54. Randall T. Ethics of receiving gifts considered. JAMA 1991; 265: 442-443.
55. Bricker EM. Industrial marketing and medical ethics. N Engl J Med 1989; 320: 1690-1692.
56. Prades J. Los empresarios preparan un código ético para evitar las sospechas de soborno a funcionarios. El País 25 de junio de 2000; 22.
57. Beary JF. Pharmaceutics. I Pharmaceutical industry. En: Encyclopedia of bioethics. Nueva York: Macmillan Library Reference, 1995.
58. Pharmaceutical promotions. N Engl J Med 327: 1686-1688.
59. Orlowski JP, Wateska L. The effects of pharmaceutical firm enticements on physician prescribing patterns. There's no such thing as a free lunch. Chest 1992; 102: 270-273.
60. Wazana A. Physicians and the pharmaceutical industry. Is a gift ever just a gift? JAMA 2000; 283: 373-380.
61. Council on Ethical and Judicial Affairs of the American Medical Association. Gifts to physician from industry. JAMA 1991; 265: 501.
62. American College of Physicians. Ethics Manual. Fourth Edition. Ann Intern Med 1998; 128: 576-595.
63. Noble RC. Gifts to physicians from industry. JAMA 1991; 266: 2222.
64. Waud DR. Gifts from Industry: Laundering money or supporting education? JAMA 1994; 271: 505.
65. Jacobs A. But doctors do see them: «freebies» seem disproportionately important. Br Med J 1999; 319: 1002.